Company

Beam Therapeutics Inc.

Headquarters: Cambridge, MA, United States

Employees: 341

CEO: Mr. John M. Evans M.B.A.

NASDAQ: BEAM -0.46%

Market Cap

$2.12 Billion

USD as of Jan. 1, 2024

Market Cap History

Beam Therapeutics Inc. market capitalization over time

Evolution of Beam Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Beam Therapeutics Inc.

Detailed Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Beam Therapeutics Inc. has the following listings and related stock indices.


Stock: NASDAQ: BEAM wb_incandescent

Details

Headquarters:

26 Landsdowne Street

2nd Floor

Cambridge, MA 02139

United States

Phone: 857 327 8775